GlassScriptPhysician profile
Changjian Chen
NPI 1649223272
$1,291.79
in general payments reported to CMS, 2019-2025
23 companies · $423 in 2025
The $423 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $85.76 · 2021: $35.15 · 2022: $117 · 2023: $108 · 2024: $232 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $763.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $292.95 | 2019-2025 | Skyrizi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.25 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.58 | 2019-2024 | Entyvio, Eohilia |
| Pfizer INC. | $81.86 | 2019-2025 | |
| Janssen Biotech, INC. | $81.84 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $60.28 | 2024-2025 | Dupixent |
| Ardelyx, INC. | $56.87 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $52.46 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $50.70 | 2023-2024 | Dificid, Zerbaxa |
| Allergan, INC. | $35.90 | 2019 | |
| Celgene Corporation | $34.53 | 2023 | Zeposia |
| Gilead Sciences, INC. | $33.73 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $32.72 | 2020-2025 | |
| Genzyme Corporation | $28.34 | 2025 | |
| Ucb, INC. | $26.30 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $24.09 | 2019 | |
| Braintree Laboratories, INC. | $22.94 | 2025 | Sutab, Suflave |
| Digestive Care, INC. | $20.13 | 2025 | Pertzye |
| Aimmune Therapeutics, INC. | $15.30 | 2025 | Vowst |
| Phathom Pharmaceuticals, INC. | $14.62 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $12.73 | 2022 | |
| Nestle Healthcare Nutrition INC. | $12.62 | 2022 | |
| Alfasigma USA, INC. | $12.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Changjian Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.